RVX Resverlogix Corp.

TSX · CA · Healthcare · Biotechnology · resverlogix.com

0.0900CAD0.00%Mkt Cap: 22.57M $P/E: —3d ago

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap22.57M USD

Enterprise Value89.11M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-5.66M USD

Revenue/Share—

Last Price0.0900 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.41

PEG—

EV/EBITDA-25.64

EV/Revenue—

P/S—

P/B-0.23

EPS (TTM)-0.04

EPS (Forward)-0.22

52W Range

0.08508% of range0.1500

52W High0.1500 CAD

52W Low0.0850 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE8.73%

ROA-97.72%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.67M USD

CapEx (TTM)506.87K USD

FCF Margin—

FCF Yield-13.69%

Net Debt66.54M USD

Net Debt/EBITDA-19.15

Balance Sheet

Debt/Equity-0.23

Current Ratio0.04

Quick Ratio0.03

Book Value/Sh-0.39 CAD

Cash/Share0.00 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.344.29M

Float251.22M

Insiders26.36%

Institutions0.00%

Short Interest

Short Ratio0.1d

Short % Out.0.00%

Shares Short1.35K

Short (prev mo.)43.34K

Technical

SMA 500.0986 (-8.7%)

SMA 2000.1029 (-12.6%)

Beta1.05

S&P 52W Chg14.58%

Avg Vol (30d)29.81K

Avg Vol (10d)43.16K

Technical Indicators

RSI (14)44.0

MACD-0.0012

MACD Signal-0.0012

MACD Hist.-0.0000

BB Upper0.1018 CAD

BB Middle0.0930 CAD

BB Lower0.0842 CAD

BB Width18.98%

ATR (14)0.0058 CAD

Vol Ratio (20d)2.88x